These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 6293510

  • 1. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some cardio- or vaso-active butenolide derivatives.
    Némoz G, Prigent AF, Picq M, Pacheco H.
    Biochem Pharmacol; 1982 Nov 01; 31(21):3353-8. PubMed ID: 6293510
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF, Moore JB.
    Biochem Pharmacol; 1979 Apr 01; 28(7):1107-12. PubMed ID: 87197
    [No Abstract] [Full Text] [Related]

  • 3. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
    Murray KJ, England PJ.
    Biochem Soc Trans; 1992 May 01; 20(2):460-4. PubMed ID: 1327922
    [No Abstract] [Full Text] [Related]

  • 4. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P, Prigent AF, Lagarde M, Nemoz G.
    Mol Pharmacol; 1993 Nov 01; 44(5):1027-35. PubMed ID: 8246905
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some pentasubstituted quercetin analogs.
    Picq M, Prigent AF, Nemoz G, Pacheco H.
    Biochem Pharmacol; 1982 Sep 01; 31(17):2777-82. PubMed ID: 6291544
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD, Shahid M.
    Pulm Pharmacol; 1994 Feb 01; 7(1):1-17. PubMed ID: 8003849
    [No Abstract] [Full Text] [Related]

  • 7. The isoenzyme selectivity of AH 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity.
    Elliott KR, Berry JL, Bate AJ, Foster RW, Small RC.
    J Enzyme Inhib; 1991 Feb 01; 4(3):245-51. PubMed ID: 1645399
    [Abstract] [Full Text] [Related]

  • 8. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.
    Stehlik J, Movsesian MA.
    Expert Opin Investig Drugs; 2006 Jul 01; 15(7):733-42. PubMed ID: 16787138
    [Abstract] [Full Text] [Related]

  • 9. Effects of visnagin on cyclic nucleotide phosphodiesterases and their role in its inhibitory effects on vascular smooth muscle contraction.
    Duarte J, Lugnier C, Torres AI, Pérez-Vizcaino F, Zarzuelo A, Tamargo J.
    Gen Pharmacol; 1999 Jan 01; 32(1):71-4. PubMed ID: 9888257
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G, Prigent AF.
    Ann Pharm Fr; 1984 Jan 01; 42(2):99-112. PubMed ID: 6091520
    [No Abstract] [Full Text] [Related]

  • 11. Purification of rat heart cyclic nucleotide phosphodiesterase on column of immobilized phenylbutenolide inhibitor.
    Prigent AF, Némoz G, Pacheco H.
    Biochem Biophys Res Commun; 1980 Aug 14; 95(3):1080-9. PubMed ID: 6251827
    [No Abstract] [Full Text] [Related]

  • 12. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA.
    Circulation; 2007 Jul 17; 116(3):233-5. PubMed ID: 17638937
    [No Abstract] [Full Text] [Related]

  • 13. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
    Rusin LJ, Duell EA, Voorhees JJ.
    J Invest Dermatol; 1978 Aug 17; 71(2):154-6. PubMed ID: 210235
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the different cyclic nucleotide phosphodiesterase isoforms separated from rat brain by flavonoid compounds.
    Picq M, Dubois M, Prigent AF, Némoz G, Pacheco H.
    Biochem Int; 1989 Jan 17; 18(1):47-57. PubMed ID: 2541724
    [Abstract] [Full Text] [Related]

  • 15. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C.
    Curr Opin Pharmacol; 2011 Dec 17; 11(6):698-706. PubMed ID: 22018840
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
    Ahluwalia GS, Rhoads AR.
    Biochem Pharmacol; 1982 Mar 01; 31(5):665-9. PubMed ID: 6177320
    [Abstract] [Full Text] [Related]

  • 17. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V.
    Curr Opin Pharmacol; 2011 Dec 01; 11(6):646-8. PubMed ID: 22079477
    [No Abstract] [Full Text] [Related]

  • 18. Isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors: effects on airways smooth muscle.
    Raeburn D, Advenier C.
    Int J Biochem Cell Biol; 1995 Jan 01; 27(1):29-37. PubMed ID: 7757880
    [Abstract] [Full Text] [Related]

  • 19. Selective inhibition of rat lung cyclic AMP phosphodiesterase and cyclic GMP phosphodiesterase by cyclic nucleotides and their analogues and various drugs [proceedings].
    Butt NM, Saeed SA, Collier HO.
    Biochem Soc Trans; 1980 Jun 01; 8(3):380-1. PubMed ID: 6249674
    [No Abstract] [Full Text] [Related]

  • 20. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.
    Van Inwegen RG, Salaman P, St Georgiev V, Weinryb I.
    Biochem Pharmacol; 1979 Apr 15; 28(8):1307-12. PubMed ID: 87199
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.